DE102006062264A1 - Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen - Google Patents

Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen Download PDF

Info

Publication number
DE102006062264A1
DE102006062264A1 DE102006062264A DE102006062264A DE102006062264A1 DE 102006062264 A1 DE102006062264 A1 DE 102006062264A1 DE 102006062264 A DE102006062264 A DE 102006062264A DE 102006062264 A DE102006062264 A DE 102006062264A DE 102006062264 A1 DE102006062264 A1 DE 102006062264A1
Authority
DE
Germany
Prior art keywords
xanthohumol
hepatitis
liver
isoxanthohumol
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102006062264A
Other languages
German (de)
English (en)
Inventor
Claus Dr. Hellerbrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JOH BARTH and SOHN GmbH and Co KG
Original Assignee
JOH BARTH and SOHN GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JOH BARTH and SOHN GmbH and Co KG filed Critical JOH BARTH and SOHN GmbH and Co KG
Priority to DE102006062264A priority Critical patent/DE102006062264A1/de
Priority to PCT/EP2007/011358 priority patent/WO2008077618A1/de
Priority to JP2009541912A priority patent/JP5513126B2/ja
Priority to RU2009128213/15A priority patent/RU2454996C2/ru
Priority to EP20070857069 priority patent/EP2120906B1/de
Priority to CA2672155A priority patent/CA2672155C/en
Priority to US12/520,756 priority patent/US20100029757A1/en
Publication of DE102006062264A1 publication Critical patent/DE102006062264A1/de
Priority to US14/074,332 priority patent/US20140066519A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE102006062264A 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen Ceased DE102006062264A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE102006062264A DE102006062264A1 (de) 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
PCT/EP2007/011358 WO2008077618A1 (de) 2006-12-22 2007-12-21 Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen
JP2009541912A JP5513126B2 (ja) 2006-12-22 2007-12-21 肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用
RU2009128213/15A RU2454996C2 (ru) 2006-12-22 2007-12-21 Применение ксантогумола и изоксантогумола в качестве активного вещества для профилактики и/или борьбы с заболеваниями печени
EP20070857069 EP2120906B1 (de) 2006-12-22 2007-12-21 Verwendung von xanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen
CA2672155A CA2672155C (en) 2006-12-22 2007-12-21 Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases
US12/520,756 US20100029757A1 (en) 2006-12-22 2007-12-21 Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
US14/074,332 US20140066519A1 (en) 2006-12-22 2013-11-07 Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006062264A DE102006062264A1 (de) 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen

Publications (1)

Publication Number Publication Date
DE102006062264A1 true DE102006062264A1 (de) 2008-06-26

Family

ID=39186950

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102006062264A Ceased DE102006062264A1 (de) 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen

Country Status (7)

Country Link
US (1) US20100029757A1 (https=)
EP (1) EP2120906B1 (https=)
JP (1) JP5513126B2 (https=)
CA (1) CA2672155C (https=)
DE (1) DE102006062264A1 (https=)
RU (1) RU2454996C2 (https=)
WO (1) WO2008077618A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016409A1 (en) * 2012-07-26 2014-01-30 Ta-Xan Ag Uses of compositions containing a roasted extract and xanthohumol
WO2020011402A1 (de) * 2018-07-11 2020-01-16 Aquanova Ag Xanthohumol-solubilisat
US11197834B2 (en) 2017-07-11 2021-12-14 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
EP3834628A4 (en) * 2018-08-10 2022-05-04 Suntory Holdings Limited COMPOSITION FOR IMPROVING THE INTESTINAL ENVIRONMENT AND METHOD FOR IMPROVING THE INTESTINAL FLORA

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2641596T (lt) * 2009-11-26 2018-08-10 Genfit 1,3-difenilprop-2-en-1-ono darinių panaudojimas kepenų sutrikimų gydymui
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EP2861202B1 (en) 2012-06-18 2018-07-18 3M Innovative Properties Company Powder composition for air polishing the surface of hard dental tissue
WO2014099490A2 (en) 2012-12-17 2014-06-26 3M Innovative Properties Company Device for dispensing a dental material with locking mechanism
EP2742898A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Powder jet device for dispensing a dental material
EP2742897A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Nozzle head, hand piece and powder jet device for applying a dental material
US20180193287A1 (en) * 2015-07-02 2018-07-12 John I. Haas, Inc. Hops-based substance and use of the substance
WO2018117041A1 (ja) * 2016-12-20 2018-06-28 サントリーホールディングス株式会社 イソキサントフモールを含む脂質代謝促進用組成物
JP7307073B2 (ja) * 2018-08-10 2023-07-11 サントリーホールディングス株式会社 尿酸排出促進用組成物、ｕｒａｔ１阻害用組成物及び血中尿酸値低下用組成物
AU2019317043A1 (en) * 2018-08-10 2021-02-04 Suntory Holdings Limited Composition and method for suppressing increase in blood glucose level
SG11202100258PA (en) * 2018-08-10 2021-02-25 Suntory Holdings Ltd Agent for suppressing microbial growth, method for preventing microbial contamination, and beverage
WO2022173750A1 (en) * 2021-02-09 2022-08-18 Oregon State University Xanthohumol derivatives and methods for making and using
CA3225379A1 (en) * 2021-07-09 2023-01-12 Devrim ARAN Prenylated chalcone and flavonoid compositions for use in treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666051A2 (en) * 2000-04-10 2006-06-07 Takara Bio, Inc. Remedies
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤
WO2007016578A2 (en) * 2005-07-29 2007-02-08 Bioactives, Inc. Prenylflavonoid formulations
WO2007021694A2 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07285856A (ja) * 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
DK0938304T3 (da) * 1996-08-30 2005-03-14 Nps Pharma Inc Isovaleramid til behandlingen af kramper, epilepsi, hovedpine og spasticitet
US6555523B1 (en) 1999-07-08 2003-04-29 Patrick T. Prendergast Use of cirsiliol and derivatives to treat infections
JP3293601B2 (ja) * 1999-09-03 2002-06-17 松下電器産業株式会社 管球およびその製造方法
US20040156950A1 (en) * 2001-04-05 2004-08-12 Green Martin Richard Use of hop components in foods
EP1415657A4 (en) * 2001-07-13 2005-09-14 Takara Bio Inc DRUG
DE10308864B4 (de) 2003-02-28 2007-03-01 Paulaner Brauerei Gmbh & Co. Kg Neues Brauverfahren, damit gebrautes Bier und dessen Verwendung
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
WO2006099015A2 (en) * 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666051A2 (en) * 2000-04-10 2006-06-07 Takara Bio, Inc. Remedies
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤
WO2007016578A2 (en) * 2005-07-29 2007-02-08 Bioactives, Inc. Prenylflavonoid formulations
WO2007021694A2 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Buckwold, V.E. [u.a.]: Antiviral activity of hop constituents against a series of DNA and RNA viruses, In: Antivir. Res., 2004, Vol. 61, S. 57- 62
Buckwold, V.E. [u.a.]: Antiviral activity of hop constituents against a series of DNA and RNA viruses, In: Antivir. Res., 2004, Vol. 61, S. 5762 *
JP 2006306800 A und Ansprüche sowie Beschreibung als Computer-Übersetzung *
JP 2006306800 AA und Ansprüche sowie Beschreibung als Computer-Übersetzung

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016409A1 (en) * 2012-07-26 2014-01-30 Ta-Xan Ag Uses of compositions containing a roasted extract and xanthohumol
US9782362B2 (en) 2012-07-26 2017-10-10 Ta-Xan Ag Uses of compositions containing a roasted extract and xanthohumol
US11197834B2 (en) 2017-07-11 2021-12-14 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
US11344509B2 (en) 2017-07-11 2022-05-31 Aquanova Ag Solubilizate with curcumin and boswellia and xanthohumol
US11931322B2 (en) 2017-07-11 2024-03-19 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
US12144784B2 (en) 2017-07-11 2024-11-19 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
WO2020011402A1 (de) * 2018-07-11 2020-01-16 Aquanova Ag Xanthohumol-solubilisat
US11786484B2 (en) 2018-07-11 2023-10-17 Aquanova Ag Xanthohumol solubilizate
EP3834628A4 (en) * 2018-08-10 2022-05-04 Suntory Holdings Limited COMPOSITION FOR IMPROVING THE INTESTINAL ENVIRONMENT AND METHOD FOR IMPROVING THE INTESTINAL FLORA

Also Published As

Publication number Publication date
JP2010513360A (ja) 2010-04-30
JP5513126B2 (ja) 2014-06-04
RU2009128213A (ru) 2011-01-27
RU2454996C2 (ru) 2012-07-10
WO2008077618A1 (de) 2008-07-03
CA2672155A1 (en) 2008-07-03
EP2120906A1 (de) 2009-11-25
CA2672155C (en) 2013-10-01
EP2120906B1 (de) 2015-04-22
US20100029757A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
DE102006062264A1 (de) Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
DE60119534T2 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
US7138148B2 (en) Use of extracts of Ginkgo biloba for preparing a medicament intended to treat sarcopenia
EP1212072B1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
EP0807435A2 (de) Indirekter HMG-CoA-Reduktase-Hemmer
WO2017001020A1 (de) Substanz auf hopfenbasis sowie verwendung der substanz
DE69424679T2 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
EP2581082B1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Status asthmaticus
DE102012000976A1 (de) Zusammensetzung für die topische Behandlung
US20170368127A1 (en) A composition comprising combined extracts of schisandra fructus, eucommiae cortex and lycii fructus for preventing or treating metabolic bone diseases
DE202011004425U1 (de) Zusammensetzung zur Anwendung bei Verdauungsbeschwerden
DE69919040T2 (de) Verwendung einer synergistischen zusammensetzung zur herstellung eines medikaments zur behandlung von lebererkrankungen
DE60102142T2 (de) Kosmetische verwendung von hopfen und ornithin
DE4308443C2 (de) Arzneimittel zur Behandlung von Retrovirusinfektionen
EP2355815B1 (de) Verwendung von leukotrien-inhibitoren zur behandlung von lungenerkrankungen bei frühgeborenen kindern
EP1605952B1 (de) Verwendung von 5-substituierten nukleosiden zur verstärkung der apoptotischen wirkung von zytostatika
KR20230016574A (ko) 괄루인 추출물을 유효성분으로 함유하는 기억력 개선, 인지 장애 또는 퇴행성 뇌질환 예방 또는 치료용 조성물
CN1686242A (zh) 具有高血脂及心脑血管疾病疗效的组合物
EP1996207B1 (en) Compositions comprising chitosan suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome
DE19854143A1 (de) Pharmazeutisches Präparat mit trypanozider und blutschizontozider Wirkung
CN109394960A (zh) 一种治疗高血压的中药组合物及其制备方法
Leumann Leaves from my plague note-book
HEROIN UBLIC HEALTH ABSTRACTS
KR20190073082A (ko) 시지지움 큐미니 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물
CN107648225A (zh) 一种抗高血压的西药组合物及其制备方法

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection